Position:
Associate Professor
Director, St. Paul’s Hospital ILD Clinic
Head, Division of Respiratory Medicine, Providence Health Care
Physician Program Director (Lung), Providence Health Care
Division:
Respiratory
Research Interests:

Interstitial lung disease, idiopathic pulmonary fibrosis, combined pulmonary fibrosis and emphysema, dyspnea, pulmonary rehabilitation, symptom management, health care databases.

Research Summary:

1. Guideline development. I have participated in several international clinical practice guidelines / consensus statements. I was on an international committee that produced an official American Thoracic Society / European Respiratory Society consensus statement on the classification of the idiopathic interstitial pneumonias. I was one of five sub-committee chairs and served on the writing committee. I chaired the Evidence-Based Medicine sub-committee for a consensus statement on acute exacerbation of idiopathic pulmonary fibrosis and for a Fleischner Society white paper on the diagnosis of idiopathic pulmonary fibrosis. I am also a member of an American Thoracic Society / European Respiratory Society / Japanese Respiratory Society / Latin American Thoracic Society international guideline on the diagnosis of idiopathic pulmonary fibrosis and another American Thoracic Society / European Respiratory Society guideline on the use of oxygen therapy in adults with chronic lung disease.
2. Canadian Registry for Pulmonary Fibrosis. I obtained funding (1.65M), coordinated design, and am chair of the CAnadian REgistry for Pulmonary Fibrosis (CARE-PF). This is an investigator-initiated multicentre prospective cohort of patients with interstitial lung disease that will determine the outcomes and mortality risk factors for patients with this disease. This registry currently includes over 1700 patients.
3. HOPE-IPF study. I coordinated design, obtained funding (2.1M), and am the principal investigator of an investigator-initiated multicentre randomized controlled trial: High Oxygen delivery to Preserve Exercise capacity in IPF patients treated with nintedanib: The HOPE-IPF Study. This study will determine whether oxygen supplementation during high-intensity exercise leads to better outcomes in 88 patients with idiopathic pulmonary fibrosis. The results of this study have the potential to substantially change clinical practice in idiopathic pulmonary fibrosis and other interstitial lung diseases. The study has currently enrolled 29 patients.

Education:
B.Sc.H, Life Sciences, Queen’s University
MD, Medicine, University of Western Ontario
Resident, Internal Medicine, University of British Columbia
Fellow, Respiratory Medicine, University of British Columbia
Fellow, Clinical Investigator Program, University of British Columbia
Fellow, Interstitial Lung Disease, University of California San Francisco
MAS, Masters in Clinical Research, University of California San Francisco
Recent Publications:

Selected Publications:

  • Khalil N, Manganas H, Ryerson CJ, Shapera S, Cantin A, Hernandez P, Turcotte E, Parker J, Moran J, Albert G, Sawtell R, Hagerimana A, Laurin P, Gagnon L. Cesari F, Kolb M. Phase 2 clinical trial of PBI-4050 in patients with idiopathic pulmonary fibrosis. European Respiratory Journal. E-published Dec 21, 2018.
  • Johannson KA, Hambly N, Assayag D, Ryerson CJ. Update in the diagnostic approach to fibrotic interstitial lung disease. Canadian Journal of Respiratory, Critical Care and Sleep Medicine. In press.
    Milne K, Chan C, Fisher JH, de Boer K, Ryerson CJ. Systematic review of content and quality of idiopathic pulmonary fibrosis review articles. European Respiratory Journal Open Research. 2018 Dec 21;4(4): 00156-2018.
  • Molgat-Seon Y, Schaeffer MR, Ryerson CJ, Guenette JA. Exercise pathophysiology in interstitial lung disease. Clinics in Chest Medicine. In press.
  • Grewal JS, Morisset J, Fisher JH, Churg AM, Bilawich AM, Ellis J, English JC, Hague JC, Khalil N, Leipsic J, Mayo J, Muller NL, Murphy D, Wright JL, Ryerson CJ. Role of a regional multidisciplinary conference in the diagnosis of interstitial lung disease. Annals of the American Thoracic Society. E-published Jan 4, 2019.
  • Goobie GC, Guler SA, Johannson KA, Fisher JH, Ryerson CJ. YouTube videos as a source of misinformation on idiopathic pulmonary fibrosis. Annals of the American Thoracic Society. E-published Jan 4, 2019.
  • Jhajj A, Gill HP, Hague CJ, Murphy D, Elicker B, Soon J, Sulaiman N, Castillo-Saldana D, Wilcox PG, Dunne J, Lee JS, Wolters PJ, Ley B, Jones KD, Morisset J, Ryerson CJ. Pulmonary physiology is poorly associated with radiological extent of disease in systemic sclerosis-associated interstitial lung disease. European Respiratory Journal. In press.
  • Ryerson CJ, Kolb M, Richeldi L, Lee JS, Kimura T, Stowasser S, Poletti V. Effects of nintedanib in patients with idiopathic pulmonary fibrosis by GAP stage. European Respiratory Journal Open Research. In press.
  • Ryerson CJ, Kolb M, Cox G, Shapera S, Swigris JJ, Fell CD, O’Brien M, Xue C, Rassi J, Moran-Mendoza O. Real-World Patterns of Pirfenidone Use and Safety in Patients With Idiopathic Pulmonary Fibrosis in Canada: Data From INSPIRATION PLUS. Canadian Journal of Respiratory, Critical Care and Sleep Medicine. In press.
  • Wells AU, Brown KK, Flaherty KR, Kolb M, Thannickal VJ, IPF Consensus Working Group. Idiopathic interstitial pneumonia or idiopathic interstitial pneumonitis: what’s in a name? Eur Respir J. 2019 Feb 14;53(2).
  • Guler SA, Hur SA, Lear SA, Camp PG, Ryerson CJ. Body composition, muscle function, and physical performance in fibrotic interstitial lung disease: a prospective cohort study. Respiratory Research. In press.
  • Ryerson CJ, Malhotra S, Lam S, English JC, Ionescu DN. A pleural mass with pulmonary infiltrates. Thorax. 2007 Aug;62(8):666, 695.
  • Wong RY, Ryerson CJ, Ko, HH, Millington SJ, Renouf DJ, Staples, JA. A New Internet-Based Learning Resource for Internal Medicine Residents. Canadian Journal of General Internal Medicine. 2008 May;3(2):76-9.95.
  • Ryerson CJ, Churg A, Wilcox, PG. A 48-year-old woman with remote Hodgkin disease and bilateral pleural effusions. Chest. 2009 Sep;136(3):934-7.
  • Petrovic V, Ryerson CJ, Levy RD. Long-term survival in idiopathic pulmonary arterial hypertension associated with massive pulmonary artery dilatation. Canadian Respiratory Journal. In press.
  • Ryerson CJ, Nayar S, Swiston JR, Sin DD. Pharmacotherapy in pulmonary arterial hypertension: A systematic review and meta-analysis Respiratory Research. 2010, 11:12.
  • Ryerson CJ, Berkeley J, Carrieri-Kohlman VL, Pantilat SZ, Landefeld CS, Collard HR. Depression and functional status are strongly associated with dyspnea in interstitial lung disease. Chest. 2011;139(3):609-16.
  • Ryerson CJ, Collard HR. How to Build a Biomarker: IL-7 and Acute Exacerbation of IPF. Sarcoidosis Vasculitis and Diffuse Lung Diseases. 2011;28:83-84.
  • Flexman AM, Ryerson CJ, Talke PO. Hemodynamic stability following intra-arterial injection of verapamil for cerebral vasospasm. Anesthesia and Analgesia. In press.
  • Ley B, Ryerson CJ, Vittinghoff E, Ryu JH, Tomassetti S, Lee JS, Poletti V, Buccioli M, Elicker BM, Jones KD, King Jr TE, Collard HR. A multidimensional index and staging system for idiopathic pulmonary fibrosis. Annals of Internal Medicine. In press.
  • Ryerson CJ, Donesky D, Pantilat SZ, Collard HR. Dyspnea in idiopathic pulmonary fibrosis: A systematic review. Journal of Pain and Symptom Management. Epub Jan 26, 2012.
Awards & Recognition:
  • 2018 Distinguished Achievement Award: Excellence in Clinical or Applied Research, Faculty of Medicine, University of British Columbia
  • 2017 Merit Award, Department of Medicine, University of British Columbia
  • 2017 Raja Abboud AZ Award of Excellence, Division of Respiratory Medicine, University of British Columbia
  • 2016 Merit Award, Department of Medicine, University of British Columbia
  • 2015 Merit Award, Department of Medicine, University of British Columbia
  • 2014-2019  Michael Smith Foundation for Health Research Career Investigator Award ($450,000)
  • 2014-2015 Dr. W. Thurlbeck Fellowship, British Columbia Lung Association ($25,000)
  • 2014-2015 Grzybowski Fellowship, British Columbia Lung Association ($25,000)
  • 2012 International Colloquium on Lung and Airways Fibrosis Junior Investigator Award
  • 2011 IPF Summit (travel award)
  • 2010-2011 Respiratory Medicine Fellowship Award, BC Lung Association ($25,000)
  • 2009-2011 Clinical Investigator Program Award, University of British Columbia ($145,930)
  • 2009-2010 Respiratory Medicine Fellowship Award, BC Lung Association ($25,000)
  • 2000-2001 Dean’s Honour List, University of Western Ontario, Undergraduate Medicine
  • 2000 Connaught Scholarship, University of Toronto ($25,000, declined)
  • 1999-2000 R.E. Semple Award, Department of Physiology, Queen’s University
  • 1998-1999 Queen’s Appeal Undergraduate Scholarship, Queen’s University
  • 1998-1999 Dean’s Honour List, Queen’s University

Summary of teaching activities
My primary appointment is as a researcher and clinician. The type and volume of my teaching sessions reflect my research and clinical expertise in the subspecialty area of interstitial lung disease. My primary contact with trainees is during inpatient respirology rotations at St. Paul’s Hospital. This involves 2-3 hours per day of face-to-face contact with trainees that predominantly includes teaching around patients, as well as a once-weekly outpatient clinic. I also conduct a monthly 1-hr teaching session on interstitial lung disease for students, residents, and pulmonary fellows, and conduct additional teaching sessions on other topics during the week as time permits (e.g., interpreting pulmonary function tests). I supervise senior respirology fellows and visiting scholars in my interstitial lung disease clinic twice per week.

I conduct several continuing medical education sessions each year. Approximately one third of these are accredited CME sessions at local hospital rounds, approximately a third are accredited CME sessions at local, national, and international conferences, and the remaining third includes non-accredited sessions. These lectures typically cover topics related to interstitial lung disease, and are attended by a variety of trainees (respirology fellows), clinicians (respirologists, general internists, family physicians), and allied health professionals (respiratory therapists, nurses, nurse practitioners). I founded the BC ILD Support Group in 2013 and lead bimonthly education sessions for this group each year (attended by 30-50 individuals each session).

Courses Taught

  • 2008-2011 UBC Internal Medicine Academic Half-day
  • 2011-Present UBC Respirology Fellowship Academic Half-day (2 sessions/year)
  • 2012-Present UBC Rheumatology Fellowship Academic Half-day (1 session/2 years)
  • 2013 UBC MSI3 Clinical Clerkship Lecture Series
  • 2013-2016 UBC MSI3 OSCE examination
  • 2013-2017 UBC MSI2 Clinical (bedside) skills
  • 2016-Present MED 419 – FLEX (flexible and enhanced learning)
  • 2017-Present MED 422D – Problem-based learning

Research trainees directly supervised in previous 5 years

Medical students: 9

Residents/Fellows: 10

Graduate students: 7

Post-graduate fellows: 7